There are currently 587 clinical trials in Richmond, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Virginia Commonwealth University, Virginia Commonwealth University/Massey Cancer Center, GSK Investigational Site and Virginia Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects
NCT04505436
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/13/2024
Locations: Virginia Commonwealth University (VCU) Medical Center, Richmond, Virginia
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Long-Term Development of Muscular Dystrophy Outcome Assessments
NCT05989620
Recruiting
This is a 24-month, observational study of up to 1000 participants with Limb Girdle Muscular Dystrophy (LGMD), Myotonic Dystrophy Type 2 (DM2), and late onset Pompe disease (LOPD).
Gender:
All
Ages:
Between 6 years and 50 years
Trial Updated:
05/13/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: LGMD1B, LGMD1C, LGMD1D, LGMD1E, LGMD1F, LGMD1G, LGMD1H, LGMD2A, LGMD2B, LGMD2C, LGMD2D, LGMD2E, LGMD2F, LGMD2G, LGMD2I, LGMD2J, LGMD2K, LGMD2L, LGMD2M, LGMD2N, LGMD2O, LGMD2P, LGMD2Q, LGMD2S, LGMD2T, LGMD2U, LGMD2W, LGMD2X, LGMD2Y
Register for Updates
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Pulmonary Associates of Richmond, Richmond, Virginia
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493
Recruiting
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: Virginia Commonwealth University (VCU) Massey Cancer Center, Richmond, Virginia
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743
Recruiting
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants may or may not have already had treatment for their cancer. Participation could last up to six years.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: Virginia Cancer Institute, Richmond, Virginia
Conditions: Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
Register for Updates
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
NCT04991935
Recruiting
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.
Gender:
All
Ages:
Between 12 years and 75 years
Trial Updated:
05/09/2024
Locations: McGuire Veterans Affairs Medical Center, Richmond, Virginia
Conditions: Eosinophilic Esophagitis
Register for Updates
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT04787744
Recruiting
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia
Conditions: Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Register for Updates
HEAL-IST IDE Trial
NCT05280093
Recruiting
Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/08/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Inappropriate Sinus Tachycardia
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Virginia Cancer Institute,1401 Johnston-Willis Drive, Richmond, Virginia +1 locations
Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Register for Updates
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
NCT05556824
Recruiting
This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-free days in subjects with GERD-related heartburn symptoms.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/08/2024
Locations: GI Research Partners, LLC, Richmond, Virginia
Conditions: Gastroesophageal Reflux
Register for Updates
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
NCT04614103
Recruiting
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/08/2024
Locations: VCU Medical Center (Virginia Commonwealth University), Richmond, Virginia
Conditions: Metastatic Non Small Cell Lung Cancer
Register for Updates
Using Grassroots Wellness Coaching to Enhance Reach and Sustainability of Behavioral Weight Management
NCT05544708
Recruiting
African American adults that live in economically disadvantaged areas are at an increased risk for obesity and cardiometabolic disease. The treatment program being tested in this research study aims to address these factors and increase outcomes for the study population. The purpose of this research study is to find out about the feasibility and acceptability of using house chats (HC) as a model for a weight loss program in a real-world, community-based setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Obesity
Register for Updates